California-based life sciences company Alamar Biosciences announced on Tuesday that it is opening its European headquarters and distribution centre in Milan, Italy.
Alamar said that this move represents a significant milestone in its commitment to advancing global scientific research with high-sensitivity biomarker solutions and supporting the commercialisation of its ARGO HT System.
The company's new European headquarters will serve as the central hub for its operations across Europe, improving its ability to serve to its increasing base of European customers.
Yuling Luo, PhD, Alamar chairman, founder and CEO, said: "We are thrilled to announce the opening of our European headquarters and distribution centre in Milan. This strategic expansion reflects our ongoing commitment to supporting the scientific community across Europe. Milan's dynamic environment and strategic location will allow us to better serve our customers and accelerate the delivery of our innovative solutions."
LEO Pharma reports positive phase 2b results for temtokibart in atopic dermatitis
New England Biolabs achieves B Corporation recertification
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial